Wed Sep 18 01:08:19 UTC 2024: ## IGM Biosciences CFO Sells Shares, Company Shows Mixed Signals

**Mountain View, CA** – IGM Biosciences, Inc. (NASDAQ:IGMS) CFO Tahir Misbah recently sold 1,487 shares of the company’s stock, according to SEC filings. While the sale amounted to over $17,000, Misbah still holds a significant number of shares in IGM Biosciences, suggesting continued confidence in the company’s future. The sale was reportedly to cover tax withholding obligations associated with the vesting of restricted stock units.

IGM Biosciences, a pharmaceutical company focused on developing novel immunotherapies, has recently faced both positive and negative developments. While the company reported a wider Q2 loss and adjusted its price target downwards, it also saw significant progress in its early-stage pipeline, including the advancement of its imvotamab Phase 1b study and the completion of enrollment for its aplitabart Phase 1a/1b study.

Morgan Stanley maintained an Overweight rating on IGM Biosciences, recognizing the company’s strong pipeline. However, H.C. Wainwright adjusted its price target from $12 to $11, maintaining a neutral rating due to the wider Q2 loss.

Despite the mixed signals, IGM Biosciences remains financially stable with more cash than debt on its balance sheet. Revenue growth over the past twelve months stands at an impressive 74%, indicating strong sales performance. However, the company has experienced significant gross profit margin challenges, with a margin of -6530.02% during the same period.

The stock has seen substantial gains recently, with a one-week price total return of 50.6% and a one-year price total return of 144.2%. This strong performance may attract new investors but it’s crucial to consider the company’s mixed signals and financial performance.

Investors interested in deeper analysis can explore further insights and analytics on InvestingPro, which offers comprehensive data and tips for making informed investment decisions regarding IGM Biosciences.

Read More